Scholarlink

<p>This narrative review examines the utility of gait digital biomarkers in Parkinson’s disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e.g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月21日

查看全文
  • Martina Mancini,
  • Mitra Afshari,
  • Quincy Almeida,
  • Sommer Amundsen-Huffmaster,
  • Katherine Balfany,
  • Richard Camicioli,
  • Cory Christiansen,
  • Marian L. Dale,
  • Leland E. Dibble,
  • Gammon M. Earhart,
  • Terry D. Ellis,
  • Garett J. Griffith,
  • Madeleine E. Hackney,
  • Jammie Hopkins,
  • Fay B. Horak,
  • Kelvin E. Jones,
  • Leah Ling,
  • Joan A. O’Keefe,
  • Kimberly Kwei,
  • Genevieve Olivier,
  • Ashwini K. Rao,
  • Anjali Sivaramakrishnan,
  • Daniel M. Corcos

摘要

This narrative review examines the utility of gait digital biomarkers in Parkinson’s disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e.g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.